[Apolipoprotein B and small, dense LDL-C].
Apolipoprotein B-100 (apo B-100) and small, dense LDL-C (sdLDL-C) are beneficial risk markers for CHD. Apo B-100 indicates the number of LDL particles that reflect the risk of CHD better than the LDL-C concentration. SdLDL is a lipoprotein subclass that causes arteriosclerosis with a much higher risk than large LDL. Apo B-100 is measured by a fully automated turbidimetric immunoassay, while small-dense LDL-C is measured by an enzymatic homogeneous assay with an automated analyzer. Elevated apo B-100 and sdLDL-C are observed among people with familial hypercholesterolemia, familial combined hyperlipidemia, diabetes mellitus, or metabolic syndrome, all of which lead to CHD with high probability. Although both apo B-100 and sdLDL-C are high in all of these cases, the two markers show noticeably different tendencies for each case. Familial hypercholesterolemia patients have higher apo B-100 than sdLDL-C; in contrast, people with diabetes mellitus or metabolic syndrome have higher sdLDL-C than apo B-100. Familial combined hyperlipidemia cases do not show much difference between the two values. The results of both apo B-100 or sdLDL-C can be good risk markers of CHD when tested individually, whereas the cause of CHD may be further clarified by assessing them in combination. By identifying the cause, patients can receive appropriate medical treatments. In conclusion, measuring both apo B-100 and sd LDL-C potentially implies further additional information on clinical utility.
Reagent R&D Department, Denka Seiken Co., Ltd. Gosen, 959-1695, Japan. y_ito@denka-seiken.co.jp
Yasuki
Y
Ito
D053299:Apolipoprotein B-100 / Q000097:blood*; D003327:Coronary Disease / Q000097:blood*; D006801:Humans; D006950:Hyperlipidemia, Familial Combined; D008077:Lipoproteins, LDL / Q000097:blood*; D024821:Metabolic Syndrome / Q000097:blood
D053299:Apolipoprotein B-100; D008077:Lipoproteins, LDL